Amgen Takes Antibody Patents Invalidation To Supreme Court
Amgen Inc. has asked the U.S. Supreme Court to overrule the Federal Circuit's invalidation of two patents covering its cholesterol medication Repatha, saying the circuit court's ruling "invades" the role of...To view the full article, register now.
Already a subscriber? Click here to view full article